-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Hold on Caris Life Sciences, Lowers Price Target to $22

Benzinga·03/13/2026 18:12:10
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and lowers the price target from $30 to $22.